Clinical trials
Active, not recruiting Leukemia, Biphenotypic, Acute trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 26 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Oncology Group | 4 |
| Fred Hutchinson Cancer Center | 3 |
| Center for International Blood and Marrow Transplant Research | 2 |
| City of Hope Medical Center | 2 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2 |
| M.D. Anderson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Johns Hopkins All Children's Hospital | 1 |
| Kura Oncology, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Biphenotypic, Acute | 26 |
| Leukemia, Myeloid, Acute | 17 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 16 |
| Myelodysplastic Syndromes | 12 |
| Burkitt Lymphoma | 7 |
| Lymphoma | 6 |
| Leukemia | 5 |
| Myeloproliferative Disorders | 5 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
Trials
Showing 26 to 26 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.